These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 29181278)

  • 1. An update on anticancer drug development and delivery targeting carbonic anhydrase IX.
    Kazokaitė J; Aspatwar A; Parkkila S; Matulis D
    PeerJ; 2017; 5():e4068. PubMed ID: 29181278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents.
    Winum JY; Rami M; Scozzafava A; Montero JL; Supuran C
    Med Res Rev; 2008 May; 28(3):445-63. PubMed ID: 17880011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Drug Development of Carbonic Anhydrase Inhibitors beyond the Active Site.
    Singh S; Lomelino CL; Mboge MY; Frost SC; McKenna R
    Molecules; 2018 Apr; 23(5):. PubMed ID: 29710858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Anti-Cancer Drug Development Targeting Carbonic Anhydrase IX and XII.
    Mboge MY; McKenna R; Frost SC
    Top Anticancer Res; 2015; 5():3-42. PubMed ID: 30272043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII.
    Guler OO; De Simone G; Supuran CT
    Curr Med Chem; 2010; 17(15):1516-26. PubMed ID: 20166929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting tumor-associated carbonic anhydrase IX in cancer therapy.
    Thiry A; Dogné JM; Masereel B; Supuran CT
    Trends Pharmacol Sci; 2006 Nov; 27(11):566-73. PubMed ID: 16996620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors.
    Supuran CT
    Expert Opin Investig Drugs; 2018 Dec; 27(12):963-970. PubMed ID: 30426805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain.
    Zatovicova M; Jelenska L; Hulikova A; Csaderova L; Ditte Z; Ditte P; Goliasova T; Pastorek J; Pastorekova S
    Curr Pharm Des; 2010; 16(29):3255-63. PubMed ID: 20819068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target.
    De Simone G; Supuran CT
    Biochim Biophys Acta; 2010 Feb; 1804(2):404-9. PubMed ID: 19679200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
    Cecchi A; Hulikova A; Pastorek J; Pastoreková S; Scozzafava A; Winum JY; Montero JL; Supuran CT
    J Med Chem; 2005 Jul; 48(15):4834-41. PubMed ID: 16033263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetazolamide-based [
    More KN; Lee JY; Kim DY; Cho NC; Pyo A; Yun M; Kim HS; Kim H; Ko K; Park JH; Chang DJ
    Bioorg Med Chem Lett; 2018 Mar; 28(5):915-921. PubMed ID: 29422388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of carbonic anhydrase IX as a novel anticancer mechanism.
    Supuran CT
    World J Clin Oncol; 2012 Jul; 3(7):98-103. PubMed ID: 22787577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of carbonic anhydrase IX: a new strategy against cancer.
    Winum JY; Scozzafava A; Montero JL; Supuran CT
    Anticancer Agents Med Chem; 2009 Jul; 9(6):693-702. PubMed ID: 19601749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of human carbonic anhydrase IX in Xenopus oocytes and MDA-MB-231 breast cancer cells.
    Kazokaitė J; Ames S; Becker HM; Deitmer JW; Matulis D
    J Enzyme Inhib Med Chem; 2016; 31(sup4):38-44. PubMed ID: 27557419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with (68)Ga-Labeled Benzenesulfonamides.
    Lau J; Zhang Z; Jenni S; Kuo HT; Liu Z; Vullo D; Supuran CT; Lin KS; Bénard F
    Mol Pharm; 2016 Mar; 13(3):1137-46. PubMed ID: 26866675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental Carbonic Anhydrase Inhibitors for the Treatment of Hypoxic Tumors.
    Supuran CT
    J Exp Pharmacol; 2020; 12():603-617. PubMed ID: 33364855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Nonpeptidic Ligand Conjugates for the Treatment of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers.
    Lv PC; Roy J; Putt KS; Low PS
    Mol Cancer Ther; 2017 Mar; 16(3):453-460. PubMed ID: 27980101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential in vitro inhibitory effects of anticancer drugs on tumor-associated carbonic anhydrase isozymes CA IX and CA XII.
    Ozensoy Guler O; Arslan O; Kockar F
    Methods Find Exp Clin Pharmacol; 2008 Jun; 30(5):335-40. PubMed ID: 18806891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors.
    Morris JC; Chiche J; Grellier C; Lopez M; Bornaghi LF; Maresca A; Supuran CT; Pouysségur J; Poulsen SA
    J Med Chem; 2011 Oct; 54(19):6905-18. PubMed ID: 21851094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
    Puccetti L; Fasolis G; Cecchi A; Winum JY; Gamberi A; Montero JL; Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2005 May; 15(9):2359-64. PubMed ID: 15837325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.